- Home
- DJCO vs KURA Comparison
DJCO vs KURA Comparison
Compare DJCO & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DJCO | KURA |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | N/A | 260 |
| Industry | Newspapers/Magazines | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.2M | 841.6M |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DJCO | KURA |
|---|---|---|
| Price | $480.55 | $8.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.56 |
| AVG Volume (30 Days) | 22.6K | ★ 1.1M |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $41,384,000.00 | ★ $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | N/A | $106.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $348.63 | $5.45 |
| 52 Week High | $674.75 | $12.49 |
Technical Indicators
Market Signals| Indicator | DJCO | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 40.78 | 46.12 |
| Support Level | $454.79 | $8.95 |
| Resistance Level | $499.68 | $9.82 |
| Average True Range (ATR) | 20.20 | 0.43 |
| MACD | -3.15 | -0.05 |
| Stochastic Oscillator | 34.16 | 23.48 |
Price Performance
Historical ComparisonAbout DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.